What is the Return on Assets (ROA) of Humacyte this year?
The Return on Assets (ROA) of Humacyte is -0.86 undefined this year.
Humacyte ROA 2025
Humacyte ROA
-0.86
Ticker
HUMA
ISIN
US44486Q1031
In 2025, Humacyte's return on assets (ROA) was -0.86, a 1,374.53% increase from the -0.06 ROA in the previous year.
Humacyte Aktienanalyse
What does Humacyte do?
Humacyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Humacyte's Return on Assets (ROA)
Humacyte's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Humacyte's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Humacyte's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Humacyte’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Humacyte stock
What was the ROA of Humacyte compared to the previous year?
The ROA of Humacyte has increased by 1,374.53% compared to the previous year.
What consequences do high ROA have for investors of Humacyte?
A high ROA is advantageous for investors of Humacyte, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Humacyte?
A low ROA can be unfavorable for investors of Humacyte as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Humacyte affect the company?
An increase in ROA of Humacyte can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Humacyte impact the company?
A reduction in the ROA of Humacyte can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Humacyte?
Some factors that can influence the ROA of Humacyte include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Humacyte important for investors?
The ROA of Humacyte is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Humacyte take to improve ROA?
To improve ROA, Humacyte can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Humacyte pay?
Over the past 12 months, Humacyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Humacyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Humacyte?
The current dividend yield of Humacyte is .
When does Humacyte pay dividends?
Humacyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Humacyte?
Humacyte paid dividends every year for the past 0 years.
What is the dividend of Humacyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Humacyte located?
Humacyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Humacyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Humacyte from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.
When did Humacyte pay the last dividend?
The last dividend was paid out on 1/15/2025.
What was the dividend of Humacyte in the year 2024?
In the year 2024, Humacyte distributed 0 USD as dividends.
In which currency does Humacyte pay out the dividend?
The dividends of Humacyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Humacyte
Our stock analysis for Humacyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Humacyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.